CN215340579U

CN215340579U - Sclera contact lens with medicine slow-releasing function

Info

Publication number: CN215340579U
Application number: CN202121520657.2U
Authority: CN
Inventors: 刘熠; 尚利如; 崔秀国; 李国丹
Original assignee: Zhuhai Weishi Aikangte Pharmaceutical Technology Co ltd; Shanghai Aikangte Medical Technology Co ltd
Current assignee: Shanghai Aikangte Medical Technology Co ltd
Priority date: 2021-07-05
Filing date: 2021-07-05
Publication date: 2021-12-28
Anticipated expiration: 2031-07-05

Abstract

The utility model provides a scleral contact lens with a drug slow release function, which comprises an optical area, an annular transition area arranged at the periphery of the optical area, and an annular landing area arranged at the periphery of the transition area, a posterior surface of the optical zone, a posterior surface of the transition zone, and a posterior surface of the landing zone to form a posterior surface of the scleral contact lens, when the scleral contact lens is worn on an eyeball, a lachrymal lens for accommodating tears can be formed among the optical area, the transition area and the cornea, the optical area is matched with the lachrymal lens for vision correction, a drug-loading area for loading drugs is arranged in at least one area of the transition area and the landing area, the drug-loading area is formed into a porous structure, maintaining the liquid medicament in the medicament-laden region by immersing the scleral contact lens in the liquid medicament.

Description

Sclera contact lens with medicine slow-releasing function

Technical Field

The utility model relates to a scleral contact lens with a drug slow release function.

Background

Contact lenses can correct refractive errors of the eye, and hard contact lenses are commonly used which are worn on the cornea by direct contact with the cornea. However, since the cornea is rich in sensory nerve cells and is a relatively sensitive part of the human body, the direct wearing of the hard contact lens on the cornea is likely to cause foreign body sensation or other discomfort symptoms of the cornea, and these symptoms are more serious for patients suffering from corneal diseases (e.g., keratoconus, dry eye, etc.). In addition, it is difficult for patients with refractive error of the abnormal cornea to obtain clear and comfortable corrected vision through ordinary hard or soft contact lenses.

In response to the above problems, the prior art proposes scleral contact lenses that land on the scleral region outside the limbus without contacting the cornea. Specifically, by increasing the diameter of the spectacle lens to make the lens larger than the entire cornea, all the contact points of the lens with the surface of the eye are changed from the cornea to the relatively insensitive sclera, so as to reduce the damage of the lens to the pathological cornea and reduce the existence of foreign body sensation of the eyeball. In particular, for some patients with damaged corneal tissue, the scleral contact lens can form a tear lens behind the lens with the cornea to contain tears, which can be used to protect the cornea. Moreover, the lachrymascope can well compensate the irregularity of the pathological cornea, so the lachrymascope is particularly suitable for improving the ametropia caused by the irregular cornea.

However, most of the conventional scleral contact lenses are scleral contact lenses without a slow release function, and in daily use, after the scleral contact lenses are worn for a long time, eyestrain, dryness or other symptoms easily appear on the eyeballs of a human body, and some symptoms such as conjunctivitis and the like are easily caused. Moreover, blood vessels on the sclera are abundant, and the sclera contact lens is thick and heavy, so that complications such as conjunctival staining and the like are easily caused.

Disclosure of Invention

In view of the above-described conventional circumstances, it is an object of the present invention to provide a scleral contact lens with a drug sustained-release function. By the scleral contact lens with the drug slow release function, the comfort level of wearing the scleral contact lens can be improved when a patient wears the scleral contact lens.

Therefore, the utility model provides a scleral contact lens with a drug slow-release function, which comprises an optical area, an annular transition area arranged at the periphery of the optical area, and an annular landing area arranged at the periphery of the transition area, a posterior surface of the optical zone, a posterior surface of the transition zone, and a posterior surface of the landing zone to form a posterior surface of the scleral contact lens, when the scleral contact lens is worn on an eyeball, a lachrymal lens for accommodating tears can be formed among the optical area, the transition area and the cornea, the optical area is matched with the lachrymal lens for vision correction, wherein a drug-loading area for loading drugs is arranged in at least one area of the transition area and the landing area, the drug-loading area is formed into a porous structure, maintaining the liquid medicament in the medicament-laden region by immersing the scleral contact lens in the liquid medicament.

In the utility model, the scleral contact lens comprises an optical area, a transition area which is arranged on the periphery of the optical area and is annular, and a landing area which is arranged on the periphery of the transition area and is annular, wherein the rear surface of the optical area, the rear surface of the transition area and the rear surface of the landing area are connected to form the rear surface of the scleral contact lens, when the scleral contact lens is worn on an eyeball, a tear lens for accommodating tears can be formed among the optical area, the transition area and a cornea, and therefore, the scleral contact lens with the vision correction effect can be formed. At least one region of the transition region and the landing region is provided with a drug-carrying region for carrying a drug, the drug-carrying region is formed into a porous structure, and the liquid drug is retained in the drug-carrying region by immersing the scleral contact lens in the liquid drug. Under the condition, the medicine carrying area of the scleral contact lens carries the medicine, so that discomfort of eyeballs can be relieved, and the comfort of the scleral contact lens is improved.

In addition, in the scleral contact lens according to the present invention, the landing zone may optionally include a limbal landing zone that contacts the limbus, and a scleral landing zone that has a contact portion for contacting the eyeball and contacts the sclera through the contact portion. This makes it possible to bring the scleral contact lens into better contact with the limbus and sclera, and thus to protect the cornea.

In addition, in the scleral contact lens according to the present invention, optionally, the posterior surface of the scleral contact lens is designed to have a continuous curved surface of a predetermined shape based on a sagittal height, the sagittal height of the posterior surface of the scleral contact lens is obtained based on a sagittal depth of an eyeball, and the sagittal height of the posterior surface of the scleral contact lens gradually decreases from the center of the optical zone to the contact portion. In this case, the scleral contact lens can be matched with the eyeball, and the problem of inaccurate corneal curvature and ametropia caused by corneal injury can be solved to a certain extent.

In addition, in the scleral contact lens according to the present invention, optionally, the contact portion includes a first section having a straight line shape in a cross section of the scleral contact lens along a rise passing through a center of the scleral contact lens. In this case, the linear contact portion can be better matched to the shape of the sclera, i.e., can be better attached to the sclera. This can improve the comfort of the scleral lens.

In addition, in the scleral contact lens according to the present invention, optionally, the sagittal height of the optical zone matches the sagittal depth of the central corneal zone of the eyeball, the sagittal height of the transition zone matches the sagittal depth of the peripheral corneal zone of the eyeball, the sagittal height of the limbal landing zone matches the sagittal depth of the limbus of the eyeball, the sagittal height of the scleral landing zone matches the sagittal depth of the sclera of the eyeball, the sagittal height of the posterior surface of the optical zone is greater than the sagittal depth of the central corneal zone of the eyeball, and the sagittal height of the posterior surface of the transition zone is greater than the sagittal depth of the peripheral corneal zone of the eyeball. Thus, a gap can exist between the scleral contact lens and the cornea, thereby facilitating the formation of a tear lens.

In addition, in the scleral contact lens according to the present invention, optionally, the optical region is a curved surface, and the transition region, the limbal land region, and the scleral land region are tapered surfaces. In this case, the optic zone can be helped to improve the effect of correcting vision, and the transition zone and limbal land can be facilitated to match the cornea, and the scleral land to the sclera.

In addition, in the scleral contact lens according to the present invention, optionally, when the opening of the drug loading region is provided on the rear surface of the scleral contact lens, and when the scleral contact lens is worn on the eyeball, the liquid drug held in the drug loading region diffuses toward tear liquid between the scleral contact lens and the eyeball. In this case, the drug in the drug-loaded region is facilitated to continuously and slowly interact with tear fluid between the scleral contact lens and the eyeball, and thus, when the scleral contact lens is used by a patient, symptoms such as discomfort of the eyeball can be effectively relieved.

Further, in the scleral contact lens according to the present invention, optionally, the liquid medicine includes at least one of an anti-VEGF, an antibiotic, or an anti-inflammatory agent.

In addition, in the scleral contact lens according to the present invention, the porous structure optionally has a plurality of micropores, and the micropores are of a blind hole design. This can promote the circulation of the liquid between the liquid medicine and the tear fluid.

In addition, in the scleral contact lens according to the present invention, the pores of the porous structure may be uniformly distributed.

According to the present invention, a drug-loaded scleral contact lens that can be well matched to the sclera and can slowly release ocular discomfort can be provided.

Drawings

Embodiments of the utility model will now be explained in further detail, by way of example only, with reference to the accompanying drawings, in which:

fig. 1 is a diagram illustrating an application scenario for placement of a drug-loaded area at a landing zone of a scleral contact lens in accordance with an example of the present invention.

Fig. 2 is a diagram illustrating an application scenario for placement of a drug-loaded region at a transition region of a scleral contact lens in accordance with an example of the present invention.

Fig. 3 is a partial schematic view illustrating the scleral landing zone shown in fig. 1.

Fig. 4 is a perspective view schematically illustrating a scleral contact lens according to an example of the present invention.

Fig. 5 is a bottom view showing the posterior surface of a scleral contact lens according to an example of the present invention.

Fig. 6 is a cross-sectional view showing a scleral contact lens according to an example of the present invention.

Reference numerals:

1 … scleral contact lens, 21 … optical zone, 22 … transition zone, 23 … landing zone, 10 … anterior surface, 20 … posterior surface, 40 … tear lens, 231 … limbal landing zone, 232 … scleral landing zone, 232a … contact, 31 … cornea, 32 … sclera.

Detailed Description

Hereinafter, preferred embodiments of the present invention will be described in detail with reference to the accompanying drawings. In the following description, the same components are denoted by the same reference numerals, and redundant description thereof is omitted. The drawings are schematic and the ratio of the dimensions of the components and the shapes of the components may be different from the actual ones.

It is noted that, as used herein, the terms "comprises," "comprising," or any other variation thereof, such that a process, method, system, article, or apparatus that comprises or has a list of steps or elements is not necessarily limited to those steps or elements expressly listed, but may include or have other steps or elements not expressly listed or inherent to such process, method, article, or apparatus.

The utility model relates to a scleral contact lens with a drug slow release function, wherein a drug loading area is arranged in at least one area of a transition area and a landing area of the scleral contact lens. Drug-loaded scleral contact lenses may also sometimes be referred to simply as "scleral contact lenses" or "scleral lenses".

Hereinafter, a scleral contact lens according to the present invention will be described in detail with reference to the accompanying drawings. In addition, the application schematic diagram described in the example of the present invention is for more clearly illustrating the technical solution of the present invention, and does not constitute a limitation on the technical solution provided by the present invention.

Fig. 1 is a diagram illustrating an application scenario for placement of a drug-loaded area at a landing zone of a scleral contact lens in accordance with an example of the present invention. Fig. 2 is a diagram illustrating an application scenario for placement of a drug-loaded region at a transition region of a scleral contact lens in accordance with an example of the present invention. Fig. 3 is a partial schematic view illustrating the scleral landing zone shown in fig. 1.

The scleral contact lens 1 according to the present embodiment may include an optical zone 21, a transition zone 22, and a landing zone 23, and the posterior surface of the optical zone 21, the posterior surface of the transition zone 22, and the posterior surface of the landing zone 23 may be connected to form the posterior surface 20 of the scleral contact lens 1.

Fig. 5 is a bottom view showing the posterior surface of a scleral contact lens according to an example of the present invention. As shown in fig. 5, in some examples, transition zone 22 can be disposed at the periphery of optical zone 21 and land zone 23 can be disposed at the periphery of transition zone 22. In some examples, the transition zone 22 and the landing zone 23 may be annular.

As shown in fig. 1, when the scleral contact lens 1 is worn on the eyeball, a tear lens 40 for accommodating tear fluid may be formed between the optical zone 21, the transition zone 22, and the cornea 31. Thus, optical zone 21 can be used to correct vision in conjunction with a lachrymal lens.

In some examples, the spacing between optical zone 21 and cornea 31 may remain substantially constant from the center of optical zone 21 to the edge of optical zone 21. In this case, tears between optical zone 21 and cornea 31 can be evenly distributed to form a relatively uniform tear mirror 40, which can provide a better optical correction.

In some examples, a drug loading area may be provided in at least one of the transition zone 22 and the landing zone 23 for carrying a drug. That is, the scleral contact lens 1 may be loaded with a drug.

In some examples, the drug loaded region may be a porous structure. In this case, when the scleral contact lens 1 is immersed in the liquid drug, the liquid drug can be held in the drug-loaded region by the porous structure.

In some examples, the posterior surface 20 of the scleral contact lens 1 may be designed to have a continuous curved surface with a predetermined shape based on the sagittal height, and the sagittal height of the posterior surface 20 of the scleral contact lens 1 may be obtained based on the sagittal depth of the eyeball. In this case, it is possible to contribute to the matching of the scleral contact lens 1 with the eyeball, and the design can solve the problem of the inaccurate corneal curvature and thus the ametropia of vision due to the corneal damage to some extent.

In some examples, the sagittal height of posterior surface 20 of scleral contact lens 1 may gradually decrease from the center of optical zone 21 to contact portion 232 a.

In some examples, the sagittal height of optic zone 21 may match the sagittal depth of the corneal optic zone of the eyeball, the sagittal height of transition zone 22 may match the sagittal depth of the peripheral corneal zone of the eyeball, the sagittal height of corneal land zone 231 may match the sagittal depth of the limbus of the eyeball, and the sagittal height of scleral land zone 232 may match the sagittal depth of sclera 32 of the eyeball.

In some examples, the optical power of optical zone 21 can be adjusted by the sagittal height of anterior surface 10 and posterior surface 20. Therefore, the vision correction device can meet the requirements of various vision correction effects. In other examples, the scleral contact lens 1 may be used to treat corneal diseases.

Fig. 6 is a cross-sectional view showing a scleral contact lens according to an example of the present invention. In some examples, optical zone 21 can be a curved surface. This can contribute to optical zone 21 providing an optical effect of correcting vision. As shown in fig. 6, in some examples, the transition zone 22, the corneal land 231, and the scleral land 232 may be conical surfaces. In this case, the transition region 22 may be linear in a cross section of the scleral contact lens 1 along the rise passing through the center of the scleral contact lens 1. This can facilitate the adaptation of the transition zone 22 to the cornea 31, i.e. the transition zone 22 can be better adapted to the peripheral region of the cornea. Likewise, the corneal land 231 may be linear in a cross-section of the scleral contact lens 1 along a sagittal height through the center of the scleral contact lens 1. Thereby, the transition zone 22 can be facilitated to match the cornea 31. That is, the corneal land 231 is better able to match the limbus.

In some examples, the land area 23 may include a corneal land area 231 that contacts the limbus. In some examples, landing zone 23 may also include a scleral landing zone 232 that contacts sclera 32, and in some examples, scleral landing zone 232 may include a contact portion 232 a. Thereby, the scleral contact lens 1 can contact the sclera 32 across the cornea 31 only through the contact portion 232 a.

In some examples, as shown in fig. 3, the scleral contact lens 1 includes a first segment having a straight line shape on a cross section along a rise passing through a center of the scleral contact lens 1. In this case, the linear contact portion 232a can be better matched to the shape of the sclera 32, that is, can be better attached to the sclera 32. Therefore, the pressure born by the sclera can be uniformly dispersed, and the comfort of the scleral lens is improved.

In some examples, the posterior surface of optic zone 21, the posterior surface of transition zone 22, and the posterior surface of landing zone 23 may form posterior surface 20 of scleral contact lens 1.

In some examples, the shape of the rear surface 20 may be substantially the same as the shape of the front surface 10. That is, the posterior surface 20 of the scleral mirror 1 may be designed parallel to the anterior surface 10. In other examples, the shape of the rear surface 20 may be different from the front surface 10. For example, the rear surface 10 may be spherical or the like.

In some examples, as shown in fig. 3, the anterior surface 10 may also include a peripheral region 12. The peripheral region 12 may surround the central region 11 and be annular.

In some examples, the peripheral region 12 may be connected with the landing zone 23. In other examples, the peripheral region 12 may be connected to the side arc region.

In some examples, a drug loading area for carrying a drug may be provided at the transition region 22 or the landing region 23. Thereby, the liquid medicine can be carried through the medicine carrying region. In other examples, a drug loading region for carrying a drug may be provided at the transition region 22 and the landing region 23.

In some examples, the drug loaded region may be a porous structure. In this case, when the scleral contact lens 1 is worn on the eyeball, the liquid medicine in the medicine carrying region may diffuse toward tear liquid located between the scleral contact lens 1 and the eyeball. Therefore, the sclera contact lens 1 can slowly release discomfort of eyeballs, and the wearing comfort of the sclera contact lens is improved.

In some examples, the opening of the drug laden region may be disposed on the posterior surface 20 of the scleral contact lens 1. However, the present embodiment is not limited thereto, and in other examples, the opening of the drug loading region may be provided on the anterior surface 10 of the scleral contact lens 1. Similarly, when the scleral contact lens 1 is worn on the eyeball, the liquid medicine in the medicine carrying area can exchange liquid with the tear liquid between the scleral contact lens 1 and the eyeball, and the wearing comfort of the scleral lens is improved through the slow release of the medicine.

In some examples, the present invention also provides a drug vial containing a drug. Specifically, the scleral contact lens 1 may be soaked in a drug vial to enable the liquid drug to fill the drug loaded area of the scleral contact lens 1. In some examples, the scleral contact lens 1 may be stored in a drug vial while the scleral contact lens 1 is idle or after use.

In some examples, the liquid drug may be an anti-VEGF, antibiotic, or anti-inflammatory agent. Specifically, the anti-VEGF may be one of norubin, avastin, or a sesamin. In some examples, the liquid drug may also be an anticoagulant, antimetabolite, or antimicrobial agent. Therefore, when the sclera contact lens 1 is worn by a patient, different symptoms can be relieved by the sclera contact lens 1 through different medicines, and the comfort degree of the sclera contact lens 1 during wearing can be improved.

In some examples, the porous structure has a plurality of micropores. In some examples, the micropores of the porous structure are of a blind via design. In this case, the liquid medicine can be relatively uniformly diffused into the tear fluid through the micropores of the blind hole design, and the liquid circulation of the liquid medicine and the tear fluid can be promoted.

In some examples, the micropores of the porous structure may be uniformly distributed. Specifically, the micropores of the porous structure may be uniformly arranged in the landing zone 23 or the transition zone 22. In other examples, the pores of the porous structure may be randomly distributed. Specifically, the micropores of the porous structure may be randomly arranged in the landing zone 23 or the transition zone 22.

In some examples, the pores of the porous structure may be in a circular, oval, or other pattern. Specifically, as shown in fig. 4, the micropores of the porous structure may be circular.

In some examples, scleral contact lens 1 may be made of a material that is biocompatible. In this case, the human eyeball can be well fitted. In some examples, the scleral contact lens 1 may be prepared from a hydrophilic material. In this case, the liquid medicine can be well held in the medicine loading region. In other examples, the scleral contact lens 1 may be made of a hydrophobic material.

In some examples, scleral contact lens 1 may be a gas permeable rigid scleral contact lens 1. In particular, the scleral contact lens 1 may be constructed of a hard, highly oxygen permeable material. In this case, it is possible to make the scleral contact lens 1 have good oxygen permeability, to improve the abrasion resistance of the scleral contact lens 1, and to facilitate the production of the scleral contact lens 1. In some examples, the stiff, highly oxygen permeable material may be selected from at least one of silicone methacrylate, fluorosilicone methacrylate, perfluoroether, fluorinated silicone.

In some examples, the scleral contact lens 1 may be constructed of a rigid, highly oxygen permeable material having an oxygen permeability coefficient (DK value) of not less than 100. In other examples, the scleral contact lens 1 may be constructed of a rigid, highly oxygen permeable material having an oxygen permeability coefficient of 100 to 200. For example, the oxygen permeability coefficient of the rigid high oxygen permeable material may be 100, 125, or 141. In this case, the scleral contact lens 1 may have good oxygen permeability so that tear fluid can provide sufficient oxygen to the cornea 31, thereby being beneficial to maintain the health of the cornea 31 and reducing the influence of oxygen deficiency of the cornea 31.

In some examples, the oxygen permeability coefficient (DK value) of the scleral contact lens 1 may be 100 to 200. Therefore, the tear liquid has better oxygen permeability, so that the tear liquid can provide sufficient oxygen for the cornea 31, and is favorable for keeping the cornea 31 healthy.

In some examples, the material comprising scleral contact lens 1 may also have resistance to sedimentation. Therefore, the protein precipitation resistance of the surface of the scleral contact lens 1 can be enhanced, thereby prolonging the life of the scleral contact lens 1.

In some examples, the scleral contact lens 1 may have a thickness of 0.2mm to 1.2 mm. Therefore, the deformation of the lens of the scleral contact lens 1 can be relieved, and the overlarge pressure on the eyeball caused by the overweight of the scleral contact lens 1 can be avoided.

In the present embodiment, the diameter of the scleral contact lens 1 may be selected according to the actual condition of the eyeball. For example, in some examples, the scleral contact lens 1 may be 14.5mm to 16.5mm in diameter. Thereby, it is able to span the cornea 31 and contact the sclera 32. In addition, the edge of the large diameter scleral contact lens 1 can be hidden under the eyelid, thereby enabling reduction of lens slippage due to eyelid movement.

In some examples, the scleral contact lens 1 may be adapted for use in patients with corneal disease to improve normal corneal function and vision, relieve pain, reduce light sensitivity, and the like. In other examples, the scleral contact lens 1 may be used for refractive correction of irregular cornea 31 and for diseases such as exposed keratitis, severe corneal dryness, and the like.

In some examples, scleral contact lens 1 may be suitable for dry eye, corneal injury, ommatidium deformity, ocular pemphigus, keratoconus, corneal ectasia, stevens-johnson syndrome, sjogren's syndrome, aniridia, neurotrophic keratitis, irregular astigmatism, post-corneal transplant complications, aberrated corneal implants, and the like.

In some examples, procedures that facilitate the use of the scleral contact lens 1 in accordance with the present invention may include: putting a liquid medicine into a medicine bottle (S100); putting the scleral contact lens 1 into a medicine bottle for soaking (S200); removing the scleral contact lens 1 from the medicine bottle (S300); the scleral contact lens 1 is removed and worn on the eyeball (S400).

In some examples, in step S100, a corresponding liquid drug may be selected for sustained release according to the discomfort symptoms of the eyeball, or a drug may be selected according to the more easily-occurring symptoms. For example, when the eyeball is easy to dry, normal saline can be placed in the medicine bottle.

In some examples, in step S200, the scleral contact lens 1 may be prepared using the sagittal height of the scleral contact lens 1 as a preparation parameter. In other words, the scleral contact lens 1 may be prepared according to the sagittal height of the anterior surface 10 and the sagittal height of the posterior surface 20 as preparation parameters.

According to the present invention, a scleral contact lens with a drug sustained-release function that can be well fitted to the sclera can be provided.

While the utility model has been described in detail in connection with the drawings and the embodiments, it is to be understood that the above description is not intended to limit the utility model in any way. Those skilled in the art can make modifications and variations to the present invention as needed without departing from the true spirit and scope of the utility model, and such modifications and variations are within the scope of the utility model.

Claims

1. A sclera contact lens with a drug slow-release function, which is characterized in that,

comprising an optical zone, a transition zone disposed at a periphery of the optical zone and having an annular shape, and a land zone disposed at a periphery of the transition zone and having an annular shape, a posterior surface of the optical zone, a posterior surface of the transition zone, and a posterior surface of the land zone being joined to form a posterior surface of the scleral contact lens,

when the scleral contact lens is worn on an eyeball, a lachrymal lens for accommodating tears can be formed among the optical area, the transition area and the cornea, the optical area is matched with the lachrymal lens for vision correction,

wherein at least one region of the transition region and the landing region is provided with a drug-loading region for carrying drugs, the drug-loading region is formed into a porous structure, and the sclera contact lens is soaked in the liquid drugs so that the liquid drugs are kept in the drug-loading region.

2. The scleral contact lens of claim 1, wherein:

the landing zone includes a limbal landing zone that contacts the limbus, and a scleral landing zone having a contact portion for contacting the eyeball and contacting the sclera through the contact portion.

3. The scleral contact lens of claim 2, wherein:

the posterior surface of the scleral contact lens is designed to have a continuous curved surface of a predetermined shape based on a sagittal height, the sagittal height of the posterior surface of the scleral contact lens is obtained based on a sagittal depth of an eyeball, and the sagittal height of the posterior surface of the scleral contact lens is gradually reduced from the center of the optical zone to the contact portion.

4. The scleral contact lens of claim 2, wherein:

the contact portion includes a first segment that is linear in a cross section of the scleral contact lens along a sagittal height passing through a center of the scleral contact lens.

5. The scleral contact lens of claim 2, wherein:

the sagittal height of the optic zone matches the sagittal depth of the central corneal zone of the eyeball, the sagittal height of the transition zone matches the sagittal depth of the peripheral corneal zone of the eyeball, the sagittal height of the limbal landing zone matches the sagittal depth of the limbus of the eyeball, the sagittal height of the scleral landing zone matches the sagittal depth of the sclera of the eyeball, the sagittal height of the posterior surface of the optic zone is greater than the sagittal depth of the central corneal zone of the eyeball, and the sagittal height of the posterior surface of the transition zone is greater than the sagittal depth of the peripheral corneal zone of the eyeball.

6. The scleral contact lens of claim 2, wherein:

the optical zone is a curved surface, and the transition zone, the limbal land zone and the scleral land zone are tapered surfaces.

7. The scleral contact lens of claim 1, wherein:

when the opening of the drug loading region is provided on the rear surface of the scleral contact lens and when the scleral contact lens is worn on the eyeball, the liquid drug held in the drug loading region diffuses toward tear liquid between the scleral contact lens and the eyeball.

8. The scleral contact lens of claim 1, wherein:

the liquid medication includes at least one of an anti-VEGF, antibiotic, or anti-inflammatory agent.

9. The scleral contact lens of claim 1, wherein:

the porous structure has a plurality of micropores, and the micropores are blind holes.

10. The scleral contact lens of claim 1, wherein:

the pores of the porous structure are uniformly distributed.